Mouthpiece ventilation (MPV) reduces hypoventilation, but its efficacy in relieving dyspnea in patients with acute chronic obstructive pulmonary disease exacerbation (AECOPD) is unclear.
Objective:
To assess the feasibility of MPV in relieving dyspnea among patients with AECOPD.
Methods:
In this prospective single-arm pilot study, the change in dyspnea on numeric rating scale (NRS) after using MPV and side effects of the treatment were studied in 18 patients with AECOPD.
Results:
The median decrease in dyspnea was 1.5 (95% confidence interval = 0.0–2.5, p = 0.006) on NRS after the intervention lasting a median of 16.9 minutes. Of the patients, 61% found MPV beneficial. The use of MPV did not increase the sense of anxiety or pain.
Conclusions:
MPV is feasible and may relieve dyspnea in patients with AECOPD, but the intervention needs further evaluation.
GoreJM, BrophyCJ, GreenstoneMA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax, 2000; 55(12):1000–1006.
2.
VermylenJH, SzmuilowiczVE, KahlanRK. Palliative care in COPD: An unmet area for quality improvement. Int J COPD, 2015; 10(1):1543–1551.
3.
RamFS, PicotJ, LightowlerJ, et al.Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2004;(3):CD004104.
4.
KeenanSP, PowersCE, McCormackDG. Noninvasive positive-pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations: A randomized controlled trial. Respir Care, 2005; 50(5):610–616.
5.
SmithTA, DavidsonPM, LamLT, et al.The use of non-invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease; A systematic review. Respirology, 2012; 17(2):300–307.
6.
BourkeSC, TomlinsonM, WilliamsTL, et al.Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial. Lancet Neurol, 2006; 5(2):140–147.
7.
HuiD, MorgadoM, ChisholmG, et al.High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: A phase II randomized trial. J Pain Symptom Manage, 2013; 46(4):463–473.
8.
NavaS, FerrerM, EsquinasA, et al.Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: A randomised feasibility trial. Lancet Oncol, 2013; 14(3):219–227.
9.
QuillCM, QuillTE. Palliative use of noninvasive ventilation: Navigating murky waters. J Palliat Med, 2014; 17(6):657–661.
10.
CuomoA. NIV in palliative care and the end of life. In: ERS Practical Handbook of Noninvasive Ventilation. (SimondsAK. Ed.) Sheffield, UK: ERS; 2015; pp. 253–259.
11.
BachJR, AlbaAS, SaporitoLR. Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users. Chest, 1993; 103(1):174–182.
12.
KhiraniS, RamirezA, DelordV, et al.Evaluation of ventilators for mouthpiece ventilation in neuromuscular disease. Respir Care, 2014; 59(9):1329–1337.
13.
LehtoJT, Leivo-KorpelaS, KorhonenT, et al.Mouthpiece ventilation in the management of dyspnea: A single-arm pilot study. Palliat Med, 2020; 34(9):1274–1278.
14.
NicoliniA, SantoM, Ferrari-BravoM, et al.Open-mouthpiece ventilation versus nasal mask ventilation in subjects with COPD exacerbation and mild to moderate acidosis: A randomized trial. Respir Care, 2014; 59(12):1825–1831.
GlerantJC, RoseD, OlteanV, et al.Noninvasive ventilation using a mouthpiece in patients with chronic obstructive pulmonary disease and acute respiratory failure. Respiration, 2007; 74(6):632–639.
17.
IyerAS, SullivanDR, LindellKO, et al.The role of palliative care in COPD. Chest, 2022; 161(5):1250–1262.
18.
JabbarianLJ, ZwakmanM, Van Der HeideA, et al.Advance care planning for patients with chronic respiratory diseases: A systematic review of preferences and practices. Thorax, 2018; 73(3):222–230.
19.
AndreasS, Alt-EppingB. Advance care planning in severe COPD: it is time to engage with the future. ERS Open Res, 2018; 4:00009-2018.
